Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

[Lipid lowering goals in high risk and very high cardiovascular risk patients: a reasonable challenge?].

Gómez-Belda A, Rodilla E, González C, Costa JA, Serra B, Pascual JM.

Rev Clin Esp. 2006 Oct;206(9):417-21. Spanish.

PMID:
17042982
3.

Suboptimal control of lipid levels: results from the non-interventional Centralized Pan-Russian Survey of the Undertreatment of Hypercholesterolemia II (CEPHEUS II).

Boytsov S, Logunova N, Khomitskaya Y; CEPHEUS II investigators.

Cardiovasc Diabetol. 2017 Dec 16;16(1):158. doi: 10.1186/s12933-017-0641-4.

5.

Lipid-lowering treatment in hypercholesterolemic patients: the CEPHEUS Thailand survey.

Sukonthasarn A, Homsanit M, Prommete B, Chotinaiwattarakul C, Piamsomboon C, Likittanasombat K.

J Med Assoc Thai. 2011 Dec;94(12):1424-34.

PMID:
22295727
7.

[Clinical use of statins and cholesterol goals in patients with several cardiovascular risk factors].

Gómez-Belda A, Rodilla E, Albert A, García L, González C, Pascual JM.

Med Clin (Barc). 2003 Oct 25;121(14):527-31. Spanish.

PMID:
14599407
8.

Achieving low-density lipoprotein cholesterol treatment goals among dyslipidemic individuals in the Levant: the CEntralized Pan-Levant survey on tHE Undertreatment of hypercholeSterolemia (CEPHEUS) study.

Hammoudeh AJ, Echtay A, Ghanem GY, Haddad J; CEPHEUS-Levant survey investigators.

Curr Med Res Opin. 2014 Oct;30(10):1957-65. doi: 10.1185/03007995.2014.929095. Epub 2014 Jun 18.

PMID:
24889279
9.

New clinical perspectives of hypolipidemic drug therapy in severe hypercholesterolemia.

Stefanutti C, Morozzi C, Di Giacomo S.

Curr Med Chem. 2012;19(28):4861-8. Review.

PMID:
22963620
11.

Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.

Cziraky MJ, Watson KE, Talbert RL.

J Manag Care Pharm. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1. Review.

PMID:
19891279
13.

Current lipid management and low cholesterol goal attainment in common daily practice in Spain. The REALITY Study.

García Ruiz FJ, Marín Ibáñez A, Pérez-Jiménez F, Pintó X, Nocea G, Ahumada C, Alemao E, Yin D; REALITY Study Group.

Pharmacoeconomics. 2004;22 Suppl 3:1-12.

PMID:
15669149
14.

The CEPHEUS Pan-Asian survey: high low-density lipoprotein cholesterol goal attainment rate among hypercholesterolaemic patients undergoing lipid-lowering treatment in a Hong Kong regional centre.

Chan RH, Chan PH, Chan KK, Lam SC, Hai JJ, Wong MK, Tam FC, Lam L, Chan CW, Lam YM, Siu DC, Tse HF, Lee SW.

Hong Kong Med J. 2012 Oct;18(5):395-406.

15.

Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.

Evans M, Roberts A, Davies S, Rees A.

Drugs. 2004;64(11):1181-96. Review.

PMID:
15161326
17.

Centralized Pan-European survey on the undertreatment of hypercholesterolemia in patients using lipid lowering drugs--the CEPHEUS-Greece survey.

Elisaf MS, Nikas N.

Angiology. 2010 Jul;61(5):465-74. doi: 10.1177/0003319710366432. Epub 2010 May 12.

PMID:
20462896
18.

The control of dyslipidemia in outpatient clinics in Greece (OLYMPIC) Study.

Diamantopoulos EJ, Athyros VG, Yfanti GK, Migdalis EN, Elisaf M, Vardas PE, Manolis AS, Karamitsos DT, Ganotakis ES, Hatseras D; OLYMPIC Study Group.

Angiology. 2005 Nov-Dec;56(6):731-41.

PMID:
16327950
19.
20.

Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.

Plans-Rubió P.

Am J Cardiovasc Drugs. 2006;6(3):177-88.

PMID:
16780391

Supplemental Content

Support Center